Horizon Discovery Group plc

Equities

HZD

GB00BK8FL363

Pharmaceuticals

Delayed London S.E. 5-day change 1st Jan Change
- GBX -.--% Intraday chart for Horizon Discovery Group plc -.--% +23.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Medical Device Innovation Consortium Partners with PerkinElmer's Horizon Discovery to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics CI
Horizon Discovery : Acquisition by PerkinElmer Completes MT
PerkinElmer (UK) Holdings Ltd. completed the acquisition of Horizon Discovery Group plc from Inclusive Capital Partners, L.P. and others. CI
Horizon Discovery : Takeover by PerkinElmer Gets Court Approval MT
Horizon Discovery : Soars 110% on Acquisition by PerkinElmer in $366 Million Deal MT
PerkinElmer (UK) Holdings Ltd. agreed to acquire Horizon Discovery Group plc from Inclusive Capital Partners, L.P. and others for approximately £290 million. CI
Transcript : Horizon Discovery Group plc, H1 2020 Earnings Call, Aug 17, 2020
Horizon Discovery Group plc Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Horizon Discovery Group plc Announces the Addition of Single Cell RNAseq-Linked Pooled CRISPR Screening to Its CRISPR Screening Services Portfolio CI
Horizon Discovery Group plc Licenses Chosource Platform to TrueBinding, Inc for Development and Commercialization of Multiple Biotherapeutics CI
Transcript : Horizon Discovery Group plc - Analyst/Investor Day
Horizon Discovery Group plc Provides Group Revenue Guidance for the Six Months Ended June 30, 2020 CI
Horizon Discovery Group plc Introduces Cas9 and dCas9-VPR Stable Cell Lines to Simplify and Accelerate CRISPR Gene Editing Workflows CI
Rentschler Biopharma Licenses Horizon Discovery's Chosource Platform to Complement Cell Line Development Offering for Difficult-To-Express Proteins CI
Horizon Discovery Group plc Announces Board Changes CI
Transcript : Horizon Discovery Group plc, 2019 Earnings Call, Apr 27, 2020
Horizon Discovery Group plc Unable to Provide Guidance for the Full Year of 2020 CI
Horizon Discovery Group plc Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Horizon Discovery Group plc's CHOSOURCE™ Platform Supports Development of Immunotherapy for Autoimmune Diseases CI
Horizon Discovery Offers CHOSOURCE™ Platform For COVID-19-Related Therapeutics and Diagnostics CI
Horizon Discovery Expands Cell-Based CRISPR Screening Services CI
Horizon Discovery Group plc Announces Positive Early-Stage Results for Novel Micro-Rna Therapeutic for Ischemic Heart Diseases CI
Horizon Discovery Group plc Provides Revenue Guidance for the Year Ended December 31, 2019 and Fiscal Year 2020 CI
Horizon Discovery Group plc Grants A Multi-Product Use License of Its Gs Knockout Cho K1 Cell Line to Ngm Biopharmaceuticals, Inc CI
Transcript : Horizon Discovery Group plc Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-13-2020 through Jan-16-2020
Chart Horizon Discovery Group plc
More charts
Horizon Discovery Group Ltd, formerly known as Horizon Discovery Group PLC, is a United Kingdom-based life science company. The Company drives the application of gene editing and gene modulation. It offers a portfolio of tools and services to help scientists understand gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.
More about the company
  1. Stock Market
  2. Equities
  3. HZD Stock
  4. News Horizon Discovery Group plc
  5. Horizon Discovery : Soars 110% on Acquisition by PerkinElmer in $366 Million Deal